Teva Pharma Makes A Bullish Move After Quarterly Beat, Business Separation Plans

During the September quarter, Teva Pharmaceutical's (TEVA) generic drugs division brought in nearly $2.2 billion in sales, above forecasts for $2.08 billion, according to FactSet. Sales in the U.S. came in well ahead of expectations, though generics in Europe and internationally were light. Overall, sales of generic drugs climbed almost 10%.